Janux Therapeutics, Inc.

NasdaqGM:JANX Stock Report

Market Cap: US$2.9b

Janux Therapeutics Management

Management criteria checks 4/4

Janux Therapeutics' CEO is David Campbell, appointed in Jun 2017, has a tenure of 7.5 years. total yearly compensation is $4.19M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $13.59M. The average tenure of the management team and the board of directors is 2.4 years and 3.8 years respectively.

Key information

David Campbell

Chief executive officer

US$4.2m

Total compensation

CEO salary percentage14.9%
CEO tenure7.5yrs
CEO ownership0.5%
Management average tenure2.4yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Dec 03

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

CEO Compensation Analysis

How has David Campbell's remuneration changed compared to Janux Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

Compensation vs Market: David's total compensation ($USD4.19M) is below average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Campbell (64 yo)

7.5yrs

Tenure

US$4,193,269

Compensation

Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...

Leadership Team

NamePositionTenureCompensationOwnership
David Campbell
President7.5yrsUS$4.19m0.46%
$ 13.6m
Charles Winter
Chief Technical Officer1.9yrsUS$1.61m0.098%
$ 2.9m
Byron Robinson
Chief Strategy Officer2.8yrsUS$1.74m0%
$ 0
Matt Whitmire
Vice President of Financeless than a yearno datano data
Maria Dobek
Principal Accounting Officer & VP of Accountingless than a yearno datano data
Tommy Diraimondo
Chief Scientific Officerless than a yearno data0.19%
$ 5.5m
James Pennington
General Counsel3.4yrsno datano data
Andy Meyer
Chief Business Officer3.8yrsno data0.13%
$ 3.8m

2.4yrs

Average Tenure

47.5yo

Average Age

Experienced Management: JANX's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Campbell
President7.5yrsUS$4.19m0.46%
$ 13.6m
Charles Hart
Member of Scientific Advisory Boardno datano datano data
Vickie Capps
Independent Director3.8yrsUS$173.01k0.13%
$ 3.8m
Ronald Barrett
Chairperson3.3yrsUS$162.69k0%
$ 0
Mark Davis
Member of Scientific Advisory Boardno datano datano data
Alana McNulty
Independent Director3.3yrsUS$166.57k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno datano datano data
Sheila Gujrathi
Director3.8yrsUS$158.01k0.21%
$ 6.3m
Winston Kung
Independent Director2.3yrsUS$164.77k0%
$ 0
Jake Simson
Independent Director3.8yrsUS$172.07k0%
$ 0
Greg Weiss
Member of Scientific Advisory Boardno datano datano data
Jennifer Maynard
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

61yo

Average Age

Experienced Board: JANX's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:31
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Janux Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Kaveri PohlmanBTIG
Justin ZelinBTIG